Vaccine innovation expert joins BOD as Meissa advances in clinical trials two intranasal live attenuated vaccine candidates (COVID-19 and...
TM
AttenuBlock: Optimized Immunity
RSV and SARS-CoV-2 are both life-threatening respiratory viruses that inhibit the immune system. Meissa’s AttenuBlock platform generates vaccine candidates that are safe, highly attenuated and specifically optimized to induce a better immune response than natural infection.
For Life and Breath
Respiratory viruses infect people from infancy to old age. Meissa’s RSV and COVID-19 vaccine candidates are designed to prevent infection and disease by inducing mucosal IgA and serum neutralizing antibodies for a multi-pronged, durable immune response.
Live Attenuated Vaccines for RSV and COVID-19
Meissa Vaccines was founded with a mission to protect people everywhere from deadly respiratory viruses and a commitment to develop innovative technologies capable of delivering effective vaccines at a global scale. Meissa is developing live attenuated vaccine candidates against life threatening respiratory viruses, including respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumoviruÂÂs (hMPV). These vaccine candidates have been developed using the company’s proprietary AttenuBlock synthetic biology and codon deoptimization platform. Meissa’s vaccine candidates are formulated to be delivered as a single, intranasal, adjuvant-free, needle-free dose and are designed to prevent infection and disease and generate a strong, durable immune response.
TM
News
Initial preclinical data shows MV-014-212 induced a SARS-CoV-2-specific mucosal IgA response, generated serum neutralizing antibodies,...
Meissa Announces 1st Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV
- The randomized, double-blind, placebo-controlled challenge study is designed to evaluate safety and prophylactic efficacy of MV-012-968...